Connect with us

Health

How CBD could help tackle opioid addiction

Published

on

“Opioids are a huge driver of overdose deaths in the US." - Sohail R. Zaidi, President of ANANDA.

A new study will explore the effect of a unique CBD technology on reducing opioid consumption in chronic pain patients.

US biotech pharma company, ANANDA have announced a second clinical trial to evaluate the effect of cannabidiol in its unique delivery technology, on opioid sparing in participants with chronic pain syndromes.

An Investigational New Drug (IND) application has been approved by the US Food and Drug Administration (FDA) for the trial, which will be led by researchers at NYU Grossman School of Medicine, using ANANDA’s proprietary Liquid Structure™ CBD.

Pre-clinical and initial clinical studies show ANANDA’s Liquid Structure technology enhances the effectiveness and stability of CBD. 

This innovation creates new potential to facilitate voluntary opioid sparing and the ability to reduce opioid intake in patients being treated for chronic pain.

“Approval of a second clinical trial with this world-renowned institution further advances applications for CBD in ANANDA’s patented delivery technology in an area that could positively impact the lives of a large number of people suffering from opioid addiction,” said Sohail R. Zaidi, ANANDA’s President.

“Opioids are a huge driver of overdose deaths in the US and non-addictive therapy is a significant unmet need.”

The trial is being conducted at NYU Grossman School of Medicine led by principal investigator Stephen Ross, MD, Associate Professor Department of Psychiatry and Director NYU Addictive Disorders and Experimental Therapeutics Research Laboratory.

 Funding for this trial is from National Institute on Drug Abuse (NIDA), with additional support from ANANDA Scientific.

“Expanding research on therapeutic alternatives to opioid pharmacotherapies for chronic pain disorders, such as CBD medicinal products, is critical to reversing the opioid epidemic,” said Dr Ross.

“ANANDA’s commitment to safe, efficacious, high-quality products, paired with their groundbreaking delivery technology, creates tremendous opportunity for the development of evidence-based CBD medicinal products to reduce opioid intake and pain. 

“We look forward to collaborating with ANANDA on this important clinical work.”

Sarah Sinclair is an award-winning freelance journalist covering health, drug policy and social affairs. She is one of the few UK reporters specialising in medical cannabis policy and as the former editor of Cannabis Health has covered developments in the European cannabis sector extensively, with a focus on patients and consumers. She continues to report on cannabis-related health and policy for Forbes, Cannabis Health and Business of Cannabis and has written for The i Paper, Byline Times, The Lead, Positive News, Leafie & others. Sarah has an NCTJ accreditation and an MA in Journalism from the University of Sunderland and has completed additional specialist training through the Medical Cannabis Clinicians Society in the UK. She has spoken at leading industry events such as Cannabis Europa.

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.